Cipla USA, Inc. has launched an authorized generic version of Aloxi in the United States under applicable agreements with Helsinn Healthcare SA, in response to the at-risk launch by Teva.
Shares of Cipla rose more than 1 percent intraday Monday as it has launched
generic version of Aloxi in the United States.
Cipla USA, Inc. has launched an authorized generic version of Aloxi in theUnited States under applicable agreements with Helsinn Healthcare SA, in
response to the at-risk launch by Teva.
Helsinn Healthcare SA currently manufactures and markets Aloxi in the United States through its licensee Eisai Inc. and its affiliate Helsinn Therapeutics (US) Inc.
Aloxi brand had US sales of approximately USD 460 million for the 12-month period ending November 2017, as per IMS Health data.
Cipla's authorized generic of Aloxi is available for shipping immediately.
At 13:40 hrs Cipla was quoting at Rs 542.40, up Rs 5.10, or 0.95 percent on the BSE.
Posted by Rakesh Patil